Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$10.65 +2.6%	$9.36	$6.38 ▼ $17.30	$1.00B	1.42	1.23 million shs	1.64 million shs
FIXX Homology Medicines		$1.18	$0.46 ▼ $17.51	$978.01M	-0.1	390,307 shs	22,300 shs
INZY Inozyme Pharma	$4.00	$3.65	$0.72 ▼ $6.24	$258.25M	2.27	944,487 shs	N/A
SIGA Siga Technologies	$6.78 +1.2%	$6.29	$4.95 ▼ $12.83	$478.66M	0.94	714,963 shs	221,368 shs
SPRB Spruce Biosciences	$0.10 +4.2%	$0.07	$0.06 ▼ $0.61	$4.08M	2.4	694,981 shs	33,969 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+2.60%	+11.52%	+12.11%	+32.63%	-37.02%
FIXX Homology Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
INZY Inozyme Pharma	0.00%	0.00%	+0.76%	+335.02%	-30.68%
SIGA Siga Technologies	+1.19%	-1.74%	+4.31%	+13.19%	-26.94%
SPRB Spruce Biosciences	+4.24%	+38.51%	+35.90%	-15.16%	-82.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	1.8485 of 5 stars	3.5	1.0	0.0	1.6	1.7	0.6
FIXX Homology Medicines	0.6532 of 5 stars	0.0	0.0	4.8	0.6	0.8	0.6
INZY Inozyme Pharma	3.4875 of 5 stars	4.2	4.0	0.0	2.7	2.5	0.0
SIGA Siga Technologies	2.2235 of 5 stars	0.0	3.0	0.0	2.0	0.8	3.1
SPRB Spruce Biosciences	2.0416 of 5 stars	3.0	3.0	0.0	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	70.58% Upside
FIXX Homology Medicines	0.00	N/A	N/A	N/A
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
SPRB Spruce Biosciences	2.00	Hold	$1.75	1,637.84% Upside

Current Analyst Ratings Breakdown

Latest FIXX, SPRB, AVDL, INZY, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	6.09	N/A	N/A	$0.77 per share	13.83
FIXX Homology Medicines	$1.16M	0.00	N/A	N/A	$1.26 per share	0.00
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
SIGA Siga Technologies	$120.33M	4.03	$0.85 per share	8.01	$3.02 per share	2.25
SPRB Spruce Biosciences	$4.91M	0.87	N/A	N/A	$1.88 per share	0.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	177.50	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
FIXX Homology Medicines	-$112.96M	-$1.96	N/A	N/A	N/A	-4,779.31%	-102.52%	-74.91%	N/A
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	10.12	5.42	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$1.32	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	8/11/2025 (Estimated)

Latest FIXX, SPRB, AVDL, INZY, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SPRB Spruce Biosciences	-$0.25	N/A	N/A	N/A	$0.67 million	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
FIXX Homology Medicines	N/A	7.25	7.25
INZY Inozyme Pharma	0.65	2.19	2.19
SIGA Siga Technologies	N/A	8.40	6.28
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
FIXX Homology Medicines	31.32%
INZY Inozyme Pharma	88.30%
SIGA Siga Technologies	55.40%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
FIXX Homology Medicines	16.10%
INZY Inozyme Pharma	12.18%
SIGA Siga Technologies	1.95%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
FIXX Homology Medicines	7	58.13 million	48.77 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
SPRB Spruce Biosciences	20	42.23 million	37.54 million	Optionable

FIXX, SPRB, AVDL, INZY, and SIGA Headlines

Recent News About These Companies

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.comM

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.comB

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.comF

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.comS

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

April 15, 2025 | seekingalpha.com

Spruce Biosciences reports delayed annual filing

April 3, 2025 | investing.com

Spruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying Value

February 5, 2025 | bovnews.comB

Hold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic Uncertainties

December 16, 2024 | markets.businessinsider.com

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

December 13, 2024 | zacks.com

JMP Securities Downgrades Spruce Biosciences (SPRB)

December 12, 2024 | msn.com

Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt

December 11, 2024 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

FIXX, SPRB, AVDL, INZY, and SIGA Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$10.65 +0.27 (+2.60%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$10.64 -0.01 (-0.05%)

As of 07/16/2025 04:48 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Siga Technologies NASDAQ:SIGA

$6.78 +0.08 (+1.19%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$6.80 +0.02 (+0.29%)

As of 07/16/2025 07:36 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Spruce Biosciences NASDAQ:SPRB

$0.10 +0.00 (+4.24%)

As of 07/16/2025 03:32 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time